

# Il follow-up degli adenomi nel programma di screening colorettales della Regione Emilia-Romagna: il clinico e l'epidemiologo

Fabio Falcini, Omero Triossi

Elaborazione dati E-R Orietta Giuliani



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA

**10 anni**  
di screening dei tumori  
del colon-retto  
nella Regione Emilia-Romagna

Seminario di studio

**Bologna, 9 aprile 2015**

# SORVEGLIANZA POSTPOLIPECTOMIA

Si considera come esame di follow-up il primo che segue al raggiungimento di un “clean colon”. Le indagini eseguite nel percorso di eradicazione di una lesione (es. un grosso polipo) e di lesioni multiple o per toilette insufficiente non vengono definite quali esami di follow-up.

Il protocollo diagnostico terapeutico dello screening per la diagnosi precoce del tumore del colon-retto - 2012



# **SORVEGLIANZA POSTPOLIPECTOMIA**

---

- ∅ Area ad elevata inappropriatazza in eccesso**
- ∅ Forte impatto nel programma di screening dei tumori del colon-retto**

# SORVEGLIANZA POSTPOLIPECTOMIA

---

- ∅ **Area ad elevata inappropriatazza in eccesso**
- ∅ **Forte impatto nel programma di screening dei tumori del colon-retto**



## PUBLICATIONS

### Publications

[GIE Journal](#)

[Practice Guidelines](#)

[Technology Reviews](#)

[PIVIs](#)

[ASGE Connection](#)

[ASGE News](#)

[SCOPE](#)

[ASGE Video Tips](#)

[ASGE Leading Edge](#)

[Endoscopic Learning Library](#)

[GESAP VII Self-Assessment](#)

[Patient Education Brochures](#)

[QR Codes poster](#)

[Anatomical images](#)

[InterLink International News](#)



### Standards of Practice

The following ASGE guidelines have been prepared by the ASGE Standards of Practice Committee, chaired by John DeWitt, MD.

### Sections

- [What's New](#)
- [Privileging and Credentialing](#)
- [Preparation for Endoscopy](#)
- [Upper GI](#)
- [Lower GI](#)
- [Biliary and Pancreatic Endoscopy](#)
- [Adverse Events](#)
- [Establishment of Gastrointestinal Endoscopy Areas](#)
- [Quality in Endoscopy](#)
- [Miscellaneous](#)

### What's New

[Quality Indicators for GI Endoscopic Procedures](#)

[SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease](#)  
Gastrointest Endosc 2015;81:489-501.e26

[The role of endoscopy in the bariatric surgery patient](#)  
Gastrointest Endosc 2015;ePub ahead of print. DOI: <http://dx.doi.org/10.1016/j.gie.2014.09.044>

[Bowel preparation before colonoscopy](#)  
Gastrointest Endosc 2015;ePub ahead of print. DOI: <http://dx.doi.org/10.1016/j.gie.2014.09.048>

[The role of ERCP in benign diseases of the biliary tract](#)  
Gastrointest Endosc 2015;ePub ahead of print. DOI: <http://dx.doi.org/10.1016/j.gie.2014.11.019>

[Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer](#)  
Gastrointest Endosc 2014;80:543-562

[Antibiotic Prophylaxis for GI Endoscopy](#)  
Gastrointest Endosc 2015;81:81-89

[The role of endoscopy in the management of constipation](#)  
Gastrointest Endosc 2014;80:563-565

[The role of endoscopy in the management of variceal hemorrhage](#)  
Gastrointest Endosc 2014;80:221-227

[Routine laboratory testing before endoscopic procedures](#)

## TABLE 3. Appropriate indications for colonoscopy<sup>39</sup>

### Surveillance of patients with neoplastic polyps

Evidence from surveys indicates that post-polypectomy surveillance colonoscopy in the United States is frequently performed at intervals that are shorter than those recommended in guidelines,<sup>55-60</sup>

# INAPPROPRIATEZZA IN ECCESSO



Comitato per la Qualità delle Prestazioni Professionali Mediche

## APPROPRIATENESS OF POST-POLYPECTOMY SURVEILLANCE COLONOSCOPY A PROSPECTIVE MULTICENTER STUDY

F. Radaelli<sup>1</sup>, S. Paggi<sup>1</sup>, O. Triossi, S. Crotta, S. Ierace, A. Lauri, P. Occhipinti, D. Drago, O. Tarantino, E. Tasini, E. Colombo, R. Pometta, L. Ferraris, P. Brosolo, R. De Marco, M. Terpin, R. Franch, S. Peyre, F. Magnolfi, M. Marini, A. Bortoli, A. Solinas, F. Monica, Z. Rossi, A. Merighi, and G. De Pretis<sup>2</sup>



XVII Congresso Nazionale  
delle Malattie Digestive  
Torino, 5-9 marzo 2011

### ***Appropriateness of timing of surveillance:***

	<b>All patients (n = 860)</b>	<b>LR patients (n= 438)</b>	<b>p-value</b>
Correct	270 (31.4%)	91 (20.7%)	< 0.001
Anticipated *	<u>462 (53.7%)</u>	<u>294 (67.2%)</u>	< 0.001
Delayed	128 (14.9%)	53 (12.1%)	NS

\* Median time of anticipation: 2.1 yr (IQR 1.6 – 2.9)

### ***Appropriateness of surveillance according to referral:***

	<b>Endoscopists (n = 561)</b>	<b>Non-endoscopists (n= 273)</b>	<b>p-value</b>
Correct	209 (37.2%)	57 (20.9%)	< 0.001



# INAPPROPRIATEZZA IN ECCESSO

## *Appropriateness of timing of surveillance in NHS screening programs:*

	<b>Screening</b> (n = 240)	<b>No Screening</b> (n= 620)	<b>p-value</b>
Correct	<u>128 (53.3%)</u>	57 (22.9%)	< 0.001
Anticipated	84 (35.1%)	378 (61.1%)	< 0.001
Delayed	28 (11.7%)	100 (16.1%)	NS



## About

Learn More about  
Choosing Wisely



See the new list from **American Association for Pediatric Ophthalmology and Strabismus**. Additional lists to be released later this year and early 2014.

How can physicians and patients have the important conversations necessary to ensure the right care is delivered at the right time? *Choosing Wisely®* aims to answer that question.

### NEWS FEED

RT @MEQualityCounts: We're thrilled to announce @MaineMedAssn's endorsement of @ABIMFoundation's #ChoosingWisely initiative!  
<http://t.co/ep...>

about 1 hour ago



*An initiative of the ABIM Foundation*

American Gastroenterological Association




## Five Things Physicians and Patients Should Question

3

**Do not repeat colonoscopy for at least five years for patients who have one or two small (< 1 cm) adenomatous polyps, without high-grade dysplasia, completely removed via a high-quality colonoscopy.**


The timing of a follow-up surveillance colonoscopy should be determined based on the results of a previous high-quality colonoscopy. Evidence-based (published) guidelines provide recommendations that patients with one or two small tubular adenomas with low grade dysplasia have surveillance colonoscopy five to 10 years after initial polypectomy. “The precise timing within this interval should be based on other clinical factors (such as prior colonoscopy findings, family history, and the preferences of the patient and judgment of the physician).”

# Raccomandazione dopo Colonscopia negativa




2012




# Raccomandazione dopo Colonscopia negativa



# Raccomandazione dopo Adenoma a basso rischio




# Raccomandazione dopo Adenoma a basso rischio




2011

# Raccomandazione dopo Adenoma ad alto rischio





# Raccomandazione dopo Adenoma ad alto rischio



# SORVEGLIANZA POSTPOLIPECTOMIA

---

- ∅ Area ad elevata inappropriatazza in eccesso
- ∅ Forte impatto nel programma di screening dei tumori del colon-retto

# IMPATTO SULLO SCREENING

## EPIDEMIOLOGIA & PREVENZIONE

Rivista dell'Associazione Italiana di epidemiologia ANNO 31 (6) NOVEMBRE-DICEMBRE 2007 SUPPLEMENTO 1



OSSERVATORIO  
NAZIONALE  
SCREENING

### Indicatori di qualità per la valutazione dei programmi di screening dei tumori coloretali

Manuale operativo

*Quality indicators for the evaluation  
of colorectal cancer screening programmes*

Operative report

A cura di: Manuel Zorzi, Priscilla Sassoli de' Bianchi,  
Grazia Grazzini, Carlo Senore  
e il gruppo di lavoro sugli indicatori del GISCoR

Prefazione Marco Zappa .....	5
Riassunto .....	6
Introduzione .....	7
La struttura della scheda .....	11
Schema riassuntivo degli indicatori .....	13
Schede degli indicatori .....	20
Alcune definizioni operative .....	40
Copertura .....	42
Il follow up degli adenomi .....	45
Il Data warehouse nazionale degli screening .....	46
Bibliografia .....	47
Allegato 1 - La classificazione TNM del cancro del colon retto .....	49
Allegato 2 - Glossario dei termini .....	51

GISCoR  
Gruppo  
Italiano  
Screening  
Coloretale




# IMPATTO SULLO SCREENING

**I**l follow up degli adenomi è un argomento cruciale per il controllo dell'appropriatezza delle prestazioni indotte dallo screening del tumore del colon retto.<sup>27</sup>

L'attività di follow up può incidere pesantemente sui carichi di lavoro degli ambulatori endoscopici, contribuendo ad allungare i tempi di attesa per l'esecuzione delle colonscopie di secondo livello, che già costituiscono un elemento di fragilità piuttosto diffuso.


# Carico endoscopico: distribuzione delle colonscopie, per tipologia

0,4



2012



# Carico endoscopico: distribuzione delle colonscopie, per tipologia



# Carico endoscopico per gestione del follow up

## Distribuzione delle colonscopie, per tipologia

### Follow up attivo



■ Approfondimento di secondo livello

■ Completamento / ripetizione

■ Follow up (dopo clean colon)


■ Altro

### Follow up passivo

2012

# Carico endoscopico per anni di attività

## Programmi con follow up attivo





# Regione Emilia-Romagna

---

- ∅ **Analisi effettuata sulle colonscopie eseguite dopo la prima colonscopia per FIT positivo**
- ∅ **Considerati tre intervalli temporali:**
  - ∅ **12 mesi  $\pm$  3 (9-15 mesi)**
  - ∅ **36 mesi  $\pm$  3 (33-39 mesi)**
  - ∅ **60 mesi  $\pm$  3 (57-63 mesi)**
- ∅ **Per il biennio 2013-14 dati fino al 30/11/14**

# Colonscopie di sorveglianza E-R

<b>ROUND</b>	<b>12 mesi</b>	<b>36 mesi</b>	<b>60 mesi</b>	<b>RCS FIT +</b>	<b>Totale</b>	<b>% FU</b>
<b>2005-06</b>	<b>175</b>	<b>0</b>	<b>0</b>	<b>15745</b>	<b>15920</b>	<b>1,1%</b>
<b>2007-08</b>	<b>1966</b>	<b>642</b>	<b>0</b>	<b>22558</b>	<b>25166</b>	<b>10.4%</b>
<b>2009-10</b>	<b>1547</b>	<b>4348</b>	<b>285</b>	<b>19629</b>	<b>25809</b>	<b>23.9%</b>
<b>2011-12</b>	<b>1224</b>	<b>3245</b>	<b>2463</b>	<b>18743</b>	<b>25675</b>	<b>27,0%</b>
<b>2013-14</b>	<b>884</b>	<b>2490</b>	<b>1777</b>	<b>17365</b>	<b>22516</b>	<b>22.9%</b>

# Regione Emilia-Romagna

---

- Ø **Analisi effettuata sulle colonscopie eseguite dopo la prima colonscopia per FIT positivo**
- Ø **Considerati tutti gli intervalli temporali:**
  - Ø **< 8 mesi            9-15 mesi            16-32 mesi**
  - Ø **33-39 mesi            40-56 mesi            57-63 mesi**
- Ø **Per il biennio 2013-14 dati fino al 30/11/14**

# Colonscopie di sorveglianza E-R

Round	≤ 8	9-15	16-32	33-39	40-56	57-63	FIT +	Tot	% FU
05-06	1821	175	17	0	0	0	15745	15937	1,2%
07-08	3155	1966	1371	642	17	0	22558	26554	15.0%
09-10	2545	1547	1595	4348	1864	285	19629	29268	32.9%
11-12	2298	1224	1090	3245	4754	2463	18743	31519	40.5%
13-14	1598	884	673	2490	6084	1777	17365	29273	40.1%

# Colonscopie di sorveglianza E-R


---


<b>10 anni di attività</b>			
<b>Follow-up</b>	<b>FIT +</b>	<b>Totale</b>	<b>% FU</b>
<b>38511</b>	<b>94040</b>	<b>132551</b>	<b>29%</b>

# Colonscopie di sorveglianza E-R

10 anni di attività

AUSL	Follow-up	FIT +	Totale	FU%
PC	1323	5613	6936	19.1%
PR	1236	8660	9896	12.4%
RE	8749	14239	22988	38.6%
MO	7214	14371	21585	33.4%
BO	7718	16584	24302	31.7%
IM	943	2493	3436	27.4%
FE	3106	8588	11694	26.6%
RA	4260	9569	13829	31.0%
FO	676	2378	3054	22.1%
CE	1357	4458	5815	23.3%
RN	1929	7087	9016	27,2%





**Notes:**

<sup>1</sup> Baseline colonoscopy must be complete in order to accurately assess risk.

<sup>2</sup> Optional additional criteria

<sup>3</sup> Other consideration: age, family history, accuracy and completeness of examination

<sup>4</sup> Clearing colonoscopy to check for missed lesions

One negative exam → **5 yearly**

Two consecutive negative exams → **Routine Screening<sup>3</sup>**

Low or intermediate risk adenomas → **B**

High risk adenomas → **C**

Negative, low or intermediate risk adenomas → **3 yearly**

Two consecutive negative exams → **5 yearly**


High risk adenomas → **C**



**Table 1.** 2012 Recommendations for Surveillance and Screening Intervals in Individuals With Baseline Average Risk

Baseline colonoscopy: most advanced finding(s)	Recommended surveillance interval (y)	Quality of evidence supporting the recommendation	New evidence stronger than 2006
No polyps	10	Moderate	Yes
Small (<10 mm) hyperplastic polyps in rectum or sigmoid	10	Moderate	No
1–2 small (<10 mm) tubular adenomas	5–10	Moderate	Yes
3–10 tubular adenomas	3	Moderate	Yes
>10 adenomas	<3	Moderate	No
One or more tubular adenomas $\geq$ 10 mm	3	High	Yes
One or more villous adenomas	3	Moderate	Yes
Adenoma with HGD	3	Moderate	No
Serrated lesions			
Sessile serrated polyp(s) <10 mm with no dysplasia	5	Low	NA
Sessile serrated polyp(s) $\geq$ 10 mm	3	Low	NA
OR			
Sessile serrated polyp with dysplasia			
OR			
Traditional serrated adenoma			
Serrated polyposis syndrome <sup>a</sup>	1	Moderate	NA

NOTE. The recommendations assume that the baseline colonoscopy was complete and adequate and that all visible polyps were completely removed.



**Fig. 1** Dichotomization of patients following a high quality colonoscopy in which high risk lesions have or have not been detected. High risk group: patients with an adenoma  $\geq 10$  mm; or with high grade dysplasia; or a villous component or  $\geq 3$  adenomas; serrated polyp  $\geq 10$  mm or with dysplasia. \* Excluding those in whom cancer has already developed. \*\* To a screening programme if available, otherwise to repetition of colonoscopy.

**2013**



## About

Learn More about  
Choosing Wisely



See the new list from **American Association for Pediatric Ophthalmology and Strabismus**. Additional lists to be released later this year and early 2014.

How can physicians and patients have the important conversations necessary to ensure the right care is delivered at the right time? *Choosing Wisely*® aims to answer that question.

### NEWS FEED

RT @MEQualityCounts: We're thrilled to announce @MaineMedAssn's endorsement of @ABIMFoundation's #ChoosingWisely initiative!  
<http://t.co/ep...>

about 1 hour ago





*An initiative of the ABIM Foundation*

American Gastroenterological Association



## Five Things Physicians and Patients Should Question

2

**Do not repeat colorectal cancer screening (by any method) for 10 years after a high-quality colonoscopy is negative in average-risk individuals.**

A screening colonoscopy every 10 years is the recommended interval for adults without increased risk for colorectal cancer, beginning at age 50 years. Published studies indicate the risk of cancer is low for 10 years after a high-quality colonoscopy fails to detect neoplasia in this population. Therefore, following a high-quality colonoscopy with normal results the next interval for any colorectal screening should be 10 years following that normal colonoscopy.




# Conclusioni



**ÜLa sorveglianza postpolipectomia è un'area ad elevata inappropriatazza in eccesso**

**ÜLa sorveglianza rappresenta una quota rilevante del carico endoscopico indotto dai programmi di screening**

**ÜSi potrebbe cominciare a valutare la possibilità di sospensione per 10 anni dopo colonscopia negativa di alta qualità?**



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA

**10 anni**  
**di screening dei tumori**  
**del colon-retto**  
**nella Regione Emilia-Romagna**

Seminario di studio

**Bologna, 9 aprile 2015**

# INAPPROPRIATEZZA IN ECCESSO

Surveillance recommendation according to US Multi-Society task Force on Colorectal cancer and the American Cancer Society [5,6].

Risk groups based on colonoscopy findings	Surveillance recommendations
Patients with only one or two small (<1 cm) tubular adenomas with only low-grade dysplasia (low-risk subjects)	5–10 years
Patients with 3 to 10 adenomas, or any adenoma >1 cm, or any adenoma with villous features, or high-grade dysplasia (high-risk subjects)	3 years
High risk subjects with follow-up endoscopy showing normal findings or presence of only one or two small (<1 cm) tubular adenomas with only low-grade dysplasia	5 years
Patients who have more than 10 adenomas at one examination	<3 years <sup>a</sup>
Patients with sessile adenomas that are removed piecemeal	2–6 months
Patients with small rectal hyperplastic polyps	No follow-up indication

<sup>a</sup> Clinician should consider the possibility of an underlying familial syndrome.